Target Name: WDR6
NCBI ID: G11180
Other Name(s): WDR6 variant 1 | MGC142027 | FLJ52552 | Trm734 homolog | WD repeat domain 6, transcript variant 1 | FLJ56107 | WD repeat domain 6 protein | WD repeat domain 6 | WD repeat-containing protein 6 isoform 1 | WD repeat-containing protein 6 | FLJ10218 | Trm734 | WDR6_HUMAN | MGC126756

WDR6: A Potential Drug Target for Various Diseases

WDR6 (WDR6 variant 1) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and psychiatric conditions. WDR6 is a non-coding RNA molecule that has been shown to play a role in regulating gene expression and has been linked to the development and progression of various diseases.

The WDR6 gene was first identified in the human genome in 2008 and has since been shown to be involved in the regulation of gene expression in various tissues and organs. Studies have shown that WDR6 is expressed in a variety of tissues, including brain, heart, liver, and muscle, and is involved in the regulation of gene expression in these tissues.

One of the key features of WDR6 is its ability to interact with other non-coding RNA molecules, known as microRNAs, to regulate their stability and function. This interaction between WDR6 and microRNAs is known as post-transcriptional regulation (PTR) and is a well-established mechanism for the regulation of gene expression in many organisms.

WDR6 has been shown to be involved in the regulation of a wide range of gene expression, including the expression of genes involved in cell adhesion, migration, and invasion, as well as the regulation of cell survival and apoptosis.

In addition to its role in gene expression, WDR6 has also been shown to play a role in the regulation of protein translation, a process that is responsible for the production of proteins from RNA templates. This suggests that WDR6 may be involved in the regulation of protein synthesis and may be a potential drug target for diseases that are characterized by the overproduction or dysfunction of proteins.

WDR6 has also been shown to be involved in the regulation of stem cell self-renewal and the maintenance of stem cell stemness. This suggests that WDR6 may be a potential drug target for diseases that are characterized by the failure of stem cells to maintain their self-renewal capacity or their ability to differentiate into functional tissues.

In addition to its potential drug target properties, WDR6 has also been shown to be involved in the regulation of tissue repair and regeneration. This suggests that WDR6 may be a potential drug target for diseases that are characterized by the failure of tissues to repair or regenerate properly.

Overall, the WDR6 gene has been shown to be involved in a wide range of physiological processes and has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of WDR6 in these processes and to develop effective therapies for the treatment of these diseases.

Protein Name: WD Repeat Domain 6

Functions: Enhances the STK11/LKB1-induced cell growth suppression activity. Negative regulator of amino acid starvation-induced autophagy

More Common Targets

WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2 | WSPAR | WT1 | WT1-AS | WTAP | WTAPP1 | WTIP | WWC1 | WWC2 | WWC2-AS2 | WWC3